Efeitos de doses elevadas da terbinafina e itraconazol em ratos Wistar

Taking into account the importance of the itraconazole and terbinafine in the antifungal therapy, the study has as objective evaluate the effects of high itraconazole doses (100 mg/kg) and terbinafine (250 mg/kg) in rats albino Wistar through the analyses of the hepatic enzymes (ALT and ALP), complete blood count and histopathologic study of different organs. The drugs were administered orally once a day, for a period of 30 days, when blood was collected and accomplished the necropsy of the experimental animals. The detected values of the hepatic enzymes and of the blood count were compatible to the physiologic indexes for the studied species with no statistical differences among the experimental groups. The histopathologic exam did not reveal any abnormality, however 25% of the treated with terbinafine died immediately after the administration of the drug. With those results we concluded that the administered doses of the drugs did not alter the appraised hepatic enzymes, as well as the blood count. However, more studies are needed to consider high doses of the terbinafine and itraconazole as viable treatment alternative for systemic mycosis.

[1]  Z. Lozano,et al.  Hepatitis tóxica colestásica por terbinafina: Reporte de caso , 2004 .

[2]  Y. Saral,et al.  Sporotrichosis Successfully Treated with Terbinafine and Potassium Iodide: Case Report and Review of the Literature , 2004, Mycopathologia.

[3]  B. Wanke,et al.  Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998-2001). , 2004, Journal of the American Veterinary Medical Association.

[4]  S. Emady-Azar,et al.  Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day−1) in the treatment of cutaneous or lymphocutaneous sporotrichosis , 2004, Mycoses.

[5]  F. Odds Antifungal agents: their diversity and increasing sophistication , 2003 .

[6]  H. Vanden Bossche,et al.  Antifungal agents of use in animal health--practical applications. , 2003, Journal of veterinary pharmacology and therapeutics.

[7]  K. Goa,et al.  Terbinafine , 2003, American journal of clinical dermatology.

[8]  A. McLachlan,et al.  Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans , 2002, Antimicrobial Agents and Chemotherapy.

[9]  M. Lucas,et al.  Acompanhamento de um modelo de indução de cirrose em ratos mediante vídeolaparoscopia , 2000 .

[10]  M. Ghannoum,et al.  An evaluation of the in vitro activity of terbinafine. , 2000, Medical mycology.

[11]  R. Hajjeh,et al.  Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Papich,et al.  Antifungal dermatologic agents: azoles and allylamines. , 2000 .

[13]  B. D. de Pauw New antifungal agents and preparations. , 2000, International journal of antimicrobial agents.

[14]  Ryder Ns Activity of terbinafine against serious fungal pathogens. , 1999 .

[15]  Ryder Ns,et al.  Activity of terbinafine against serious fungal pathogens , 1999, Mycoses.

[16]  A. Pérez Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases , 1999, Mycoses.

[17]  Hay Therapeutic potential of terbinafine in subcutaneous and systemic mycoses , 1999, The British journal of dermatology.

[18]  J. Bennett,et al.  Efficacies of four antifungal agents in experimental murine sporotrichosis , 1988, Antimicrobial Agents and Chemotherapy.

[19]  John E. Harkness,et al.  Biology and Medicine of Rabbits and Rodents , 1983 .